microbiome technology News
-
Testing of a Drug Panel for effects on the gut Microbiome using RapidAIM
MedBiome’s founders reported in Microbiome the development of the RapidAIM platform to screen compounds against individual microbiomes in vitro. They tested 43 compounds (including 4 antibiotics) against 5 individual microbiomes using the RapidAIM technology. The RapidAIM workflow provides insights into microbiome absolute abundance and functional responses to drugs. ...
-
Our co-founders and SAB scientific publications among the Top 100 in Cell and Molecular Biology
Last week, the Nature Group Scientific Reports journal published the top 100 most downloaded cell and molecular biology papers. This comprehensive list featured an outstanding publication from our co-founders and SAB members on Precision modification of the human gut microbiota based on selective targeting of surface-associated proteins.Importantly, it is one of the few manuscripts ...
-
Microviable Therapeutics to enter into a contractual agreement with BCD Bioscience
Microviable Therapeutics SL (Gijón, Asturias, Spain), announced a contractual agreement with BCD Bioscience Inc. (California, USA) to work on microbial fermentation and novel prebiotics to modulate the human gut microbiome. Microviable expertise on gut microbiome research will enable to conveniently process microbiota samples for fermentation applications that coupled with BCD ...
-
Dr. Warren Flood steps up as CEO of Bio-Me
Microbiome precision medicine company Bio-Me today announced that Dr. Warren Flood has become CEO following his successful period as COO. Previous CEO Dr. Morten Isaksen moves up to the Board and will also continue as Chief Innovation Officer with a focus on longer term and higher-value clinical applications for the company’s Precision Microbiome Profiling (PMP™) technology. These ...
By Bio-Me
-
Intus Bio Granted Foundational Patent for High Resolution Microbiome Analysis Technology
Intus Biosciences, a microbiome research company that develops tools for characterizing microbiome populations down to the strain level, was recently awarded a new patent by the United States Patent and Trademark Office. The patent, U.S. Patent 10,894,990, was awarded January 19, 2021, for a “High Throughput Method For Identification and Sequencing of Unknown Microbial and Eukaryotic ...
-
Ferring, Rebiotix and MyBiotics Collaborate to Develop Live Microbiome-Based Therapeutics in Reproductive Medicine and Maternal Health
The collaboration aims to create standardised, stabilised live microbiota-based formulations addressing bacterial vaginosis (BV), a common vaginal infection among women of reproductive age linked to increased risk of miscarriage, problems during pregnancy and fertility issues1,2,3 The companies aim to leverage world-leading microbiome technology expertise to bring new therapeutics to this ...
-
DermBiont Announces Acquisition of SeylanMED to Expand its Portfolio of Targeted Topical Therapeutics Treating Skin Diseases at Their Root Cause
BOSTON, MA, October 21, 2020 – DermBiont, Inc., a clinical stage precision dermatology company targeting skin diseases at their root cause has expanded its pipeline and therapeutic modalities with the acquisition of SeylanMED, Inc. “This strategic acquisition delivers multi-factorial value,” said Karl Beutner, MD, PhD, Co-founder, CEO, and CMO of DermBiont. “It expands ...
-
Medbiome`s founders demonstrated that structurally similar compounds can have distinct effects on individual microbiomes
In a recent paper in Gut Microbes the founders of MedBiome reported the effects of berberine (BBR) and 16 structural analogs on seven individual gut microbiomes using our RapidAIM technology. This article clearly illustrates that the RapidAIM technology can distinguish the effects of structurally similar compounds on individual microbiomes. This is an important milestone when selecting and ...
-
MedBiome licenses the RapidAIM technology from the University of Ottawa
MedBiome is pleased to announce that it has exclusively licensed the RapidAIM technology from the University of Ottawa. RapidAIM is a revolutionary assay to rapidly determine the effects of compounds on individual human living microbiomes. RapidAIM fidelity maintains functional living human microbiomes in 96 well plates and allows the testing of drugs for their effects on the ...
-
JSR, the collaborative research facility "JSR BiRD" in Kawasaki, invites KINS Co., Ltd.
JSR Corporation (Head Office: Minato-ku, Tokyo, Representative Director and CEO: Eric Johnson, JSR Corporation) announced today that it has concluded a facility use agreement with KINS Co., Ltd. (KINS), a company with a database of human microbiome, for the Collaborative Lab, a collaborative research facility for startups, which was established in a new research laboratory at the "JSR Bioscience ...
-
Bio-Me represented with two presentations at the 6th Microbiome Movement – Drug Development Summit 2021
On July 1st Bio-Me has two back-to-back presentations. Our Founder and CEO, Morten L. Isaksen will first be presenting how we support companies in their development of microbiome modulating drugs with our PMP™ technology for targeted microbiome analysis. Following that, our COO Warren Flood will do a joint presentation with Ricardo Valladares, CSO at Siolta Therapeutics showcasing ...
By Bio-Me
-
Microbiotica Wins Young Company of the Year at Business Weekly Awards
Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, has been named Business Weekly Young Company of the Year 2020. The “Young Company of the Year” category is awarded to the most exciting recently incorporated enterprise in any sector that has made significant progress in the last 12 months. Microbiotica has been recognised for its continued development ...
-
Bio-Me restructures board with Gilhuus-Moe becoming Executive Chair
Bio-Me today announced a major board restructuring with Carl Christian Glilhuus-Moe stepping up to the Executive Chair position. He is joined by new board members Hilde Furberg, Anne-Marie Duus Kristensen, and Arne Materna who collectively bring a wealth of diagnostic, microbiology, and commercialization experience as the Company enters a new phase of development following a recent successful ...
By Bio-Me
-
Thermo Fisher Scientific Launches Axiom Microbiome Array for Research
Thermo Fisher Scientific, the world leader in serving science, recently launched the Applied Biosystems Axiom Microbiome Array for simultaneous detection of archaea, bacteria, fungi, protozoa and viruses in human and non-human samples. Developed in collaboration with the Lawrence Livermore National Laboratory (LLNL), the array is designed to increase the understanding of microorganisms, while ...
-
CD Genomics Fully Supports Your Microbiome Research with Comprehensive Sequencing Solutions
CD Genomics is a leading services company committed to providing global customers with the most comprehensive analytic services, including a broad range of microbial genomic solutions to support research and development. The company announced microbiome profiling services, alongside bioinformatic analysis technology to help researchers understand the significance of human and animal microbiota. ...
By CD Genomics
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you